Clinically Significant Macular Edema

Clinically Significant Macular Edema (CSME) is the most common form of diabetic eye disease. Caused by swelling of the central retina (maximal retinal thickening, macular edema) due to the leakage of fluid from small blood vessels within the macula, CSME results in progressive degradation of fine, detailed vision. CSME may involve the central macula (center-involving) or the outer macula.

Changes in lifestyle and diet, and increases in obesity and life expectancy rates, have led to an increased incidence of CSME. According to the National Eye Institute, CSME affects approximately 20% of patients diagnosed with diabetes.

Currently, retinal photocoagulation is considered the standard treatment for CSME. The high levels of energy used in retinal photocoagulation result in irreversible collateral damage, however. In addition, photocoagulation is often painful for the patient. The advent of shorter pulsed retinal laser treatments, such as micropulse, offer improved patient comfort, but still result in thermal damage to the retina.

Clinical studies have shown 2RT™ to be as effective as as retinal photocoagulation in reducing cystoid macular edema secondary to diabetic retinopathy., but with the added benefit of sparing the photoreceptors, and therefore retinal function, of thermal damage. Using 500 times less energy than retinal photocoagulation, 2RT™ eliminates the incidence of heat damage to the retina and surrounding cells.

2RT® has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market release for the treatment of Clinically Significant Macula Edema (CSME).

  1. Simo R and Hernandez C. Diabetologia 2008;51:1574–1580.

  2. Simo R and Hernandez C. Diabetes Care 2009;32:1556–1562.

  3. Early Treatment Diabetic Retinopathy Study Report Number 2: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology 94:761-774, 1987

  4. Casson RJ. Et al., “Pilot randomized trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema”, Clin Experiment Ophthalmol. 2012 Aug;40(6):604-10

  5. Wood JP at al., Retinal Damage Profiles and Neuronal Effects of Laser Treatment: Comparison of a Conventional Photocoagulator and a Novel 3-Nanosecond Pulse Laser, Invest Ophthalmol Vis Sci. 2013;54:2305-2318

  6. Pelosini L. et al., RETINA REJUVENATION THERAPY FOR DIABETIC MACULAR EDEMA A Pilot Study, Retina 0:1-11,2012